Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.
Spectrum Pharmaceuticals, Inc.
Equities
SPPI
US84763A1088
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |